<SEC-DOCUMENT>0001648257-25-000087.txt : 20251229
<SEC-HEADER>0001648257-25-000087.hdr.sgml : 20251229
<ACCEPTANCE-DATETIME>20251229060755
ACCESSION NUMBER:		0001648257-25-000087
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20251229
FILED AS OF DATE:		20251229
DATE AS OF CHANGE:		20251229

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HUTCHMED (China) Ltd
		CENTRAL INDEX KEY:			0001648257
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			E9

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37710
		FILM NUMBER:		251602426

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		48TH FLOOR, CHEUNG KONG CENTER
		STREET 2:		2 QUEEN'S ROAD CENTRAL
		CITY:			HONG KONG
		PROVINCE COUNTRY:   	K3
		BUSINESS PHONE:		852-2121-3888

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		48TH FLOOR, CHEUNG KONG CENTER
		STREET 2:		2 QUEEN'S ROAD CENTRAL
		CITY:			HONG KONG
		PROVINCE COUNTRY:   	K3

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Hutchison China MediTech Ltd
		DATE OF NAME CHANGE:	20150716
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>hcm-20251229x6k.htm
<DESCRIPTION>6-K
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 12/29/2025 10:51:16 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-bottom:1pt;padding-top:1pt;text-align:right;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt 1.5pt 0pt 0pt;"><font style="font-size:1pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1.2" width="25.0%" style="background-color:#000000;color:#000000;height:1.2pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="font-size:18pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-size:16pt;font-weight:bold;">FORM&#160;6-K</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="font-size:16pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1.2" width="25.0%" style="background-color:#000000;color:#000000;height:1.2pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="font-size:18pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Month of </b><b style="font-weight:bold;">December</b><b style="font-weight:bold;"> </b><b style="font-weight:bold;">2025</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Commission File Number: 001-37710</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1.2" width="25.0%" style="background-color:#000000;color:#000000;height:1.2pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">HUTCHMED (CHINA) LIMITED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">(Translation of registrant&#8217;s name into English)</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1.2" width="25.0%" style="background-color:#000000;color:#000000;height:1.2pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">48th Floor, Cheung Kong Center, 2 Queen&#8217;s Road Central, Hong Kong</b> </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">(Address of principal executive offices)</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1.2" width="25.0%" style="background-color:#000000;color:#000000;height:1.2pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form&#160;20-F or Form&#160;40-F.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">Form&#160;20-F&#160;&#160;<font style="font-family:'Times New Roman';">&#8999;</font> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form&#160;40-F&#160;&#160;<font style="font-family:'Times New Roman';">&#9723;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:4.47%;margin-right:4.47%;margin-top:30pt;page-break-after:always;width:91.06%;border-width:0;"><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">HUTCHMED (CHINA) LIMITED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form&#160;6-K</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT&#160;INDEX</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:11.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:87.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></td><td style="vertical-align:bottom;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;width:87.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr style=""><td style="vertical-align:top;width:11.19%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:87.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:9.55pt;"><td style="vertical-align:top;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Exhibit 99.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:87.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin:0pt 36pt 0pt 0pt;"><font style="font-weight:normal;">Announcement</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">relating</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">to</font><font style="font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-weight:normal;letter-spacing:-0.1pt;">b</font><font style="font-weight:normal;letter-spacing:-0.1pt;">locklisting </font><font style="font-weight:normal;letter-spacing:-0.1pt;">s</font><font style="font-weight:normal;letter-spacing:-0.1pt;">ix </font><font style="font-weight:normal;letter-spacing:-0.1pt;">m</font><font style="font-weight:normal;letter-spacing:-0.1pt;">onthly </font><font style="font-weight:normal;letter-spacing:-0.1pt;">r</font><font style="font-weight:normal;letter-spacing:-0.1pt;">eturn</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:9.55pt;"><td style="vertical-align:top;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Exhibit 99.2</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:87.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Press release relating to NDA Acceptance in China with priority review status for fanregratinib in second-line intrahepatic cholangiocarcinoma</p></td></tr><tr style="height:9.55pt;"><td style="vertical-align:top;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:87.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:9.55pt;"><td style="vertical-align:top;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:87.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:10pt;">2</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:4.47%;margin-right:4.47%;margin-top:30pt;page-break-after:always;width:91.06%;border-width:0;"><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style=""><td style="vertical-align:top;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">HUTCHMED (CHINA) LIMITED</p></td></tr><tr style=""><td style="vertical-align:top;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:41.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:41.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:41.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">/s/ Johnny Cheng</p></td></tr><tr style=""><td style="vertical-align:top;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:41.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Johnny Cheng</p></td></tr><tr style=""><td style="vertical-align:top;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:41.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Chief Financial Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Date: December 29, 2025</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:10pt;">3</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:4.47%;margin-right:4.47%;margin-top:30pt;page-break-after:avoid;width:91.06%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>hcm-20251229xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 12/29/2025 10:51:16 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;width:32.3%;">&#9;</font><font style="display:inline-block;width:11.76%;">&#9;</font><font style="display:inline-block;width:38.55%;">&#9;</font></font><font style="display:block;height:1px;left:0pt;position:absolute;width:100%;z-index:0;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><b style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:bold;">Exhibit 99.1</b></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:11pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><img src="hcm-20251229xex99d1001.gif" alt="Graphic" style="display:inline-block;height:44.95pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:160.15pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="white-space:pre-wrap;">                                              </font><font style="font-size:12pt;white-space:pre-wrap;">                                                                                                          </font><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><a name="_Hlk181768051"></a><a name="_Hlk162538399"></a><b style="font-weight:bold;">Blocklisting Six Monthly Return</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Hong Kong, Shanghai, &amp; Florham Park, NJ &#8212; </b><b style="font-weight:bold;">Monday</b><b style="font-weight:bold;">, </b><b style="font-weight:bold;">December 29, 2025</b><b style="font-weight:bold;">:</b> HUTCHMED (China) Limited (&#8220;HUTCHMED&#8221; or the &#8220;Company&#8221;) (Nasdaq/AIM: HCM; HKEX: 13) announces the following blocklisting six monthly return: </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:2.15pt;padding-right:2.15pt;table-layout:auto;width:100%;"><tr style=""><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">1.</p></td><td style="vertical-align:top;width:30.39%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">Name of applicant:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.45%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:62.15%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">HUTCHMED (China) Limited </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">2.</p></td><td style="color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:2.15pt;padding-right:2.15pt;padding-top:0pt;text-align:left;vertical-align:top;width:30.39%;" rowspan="2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">Name of scheme:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.45%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:2.15pt;padding-right:2.15pt;padding-top:0pt;text-align:left;vertical-align:top;width:62.15%;" rowspan="2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">Share Option Scheme conditionally adopted by HUTCHMED in 2015 (&#8220;2015 HUTCHMED Share Option Scheme&#8221;)</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0pt 0.9pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="display:none;vertical-align:middle;width:30.39%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"></td><td style="vertical-align:top;width:4.45%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="display:none;vertical-align:middle;width:62.15%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"></td></tr><tr style=""><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">3.</p></td><td style="vertical-align:top;width:30.39%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">Period of return:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.45%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:62.15%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">From June 29, 2025 to December 28, 2025</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:2.15pt;padding-right:2.15pt;padding-top:0pt;text-align:left;vertical-align:top;width:2.99%;" rowspan="2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">4.</p></td><td style="color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:2.15pt;padding-right:2.15pt;padding-top:0pt;text-align:left;vertical-align:top;width:30.39%;" rowspan="2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">Balance under scheme from previous return:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.45%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:2.15pt;padding-right:2.15pt;padding-top:0pt;text-align:left;vertical-align:top;width:62.15%;" rowspan="2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">2015 HUTCHMED Share Option Scheme: 45,992,018 ordinary shares of US$0.1 each</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="display:none;vertical-align:middle;width:2.99%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"></td><td style="display:none;vertical-align:middle;width:30.39%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"></td><td style="vertical-align:top;width:4.45%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="display:none;vertical-align:middle;width:62.15%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"></td></tr><tr style=""><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">5.</p></td><td style="color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:2.15pt;padding-right:2.15pt;padding-top:0pt;text-align:left;vertical-align:top;width:30.39%;" rowspan="2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return: </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.45%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:2.15pt;padding-right:2.15pt;padding-top:0pt;text-align:left;vertical-align:top;width:62.15%;" rowspan="2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">2015 HUTCHMED Share Option Scheme: Nil</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15.6pt;"><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="display:none;vertical-align:middle;width:30.39%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"></td><td style="vertical-align:top;width:4.45%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="display:none;vertical-align:middle;width:62.15%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"></td></tr><tr style=""><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">6.</p></td><td style="color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:2.15pt;padding-right:2.15pt;padding-top:0pt;text-align:left;vertical-align:top;width:30.39%;" rowspan="2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">Number of securities issued/allotted under scheme during period:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.45%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:2.15pt;padding-right:2.15pt;padding-top:0pt;text-align:left;vertical-align:top;width:62.15%;" rowspan="2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0pt 0.9pt;">2015 HUTCHMED Share Option Scheme: 216,150</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="display:none;vertical-align:middle;width:30.39%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"></td><td style="vertical-align:top;width:4.45%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="display:none;vertical-align:middle;width:62.15%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"></td></tr><tr style=""><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">7.</p></td><td style="color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:2.15pt;padding-right:2.15pt;padding-top:0pt;text-align:left;vertical-align:top;width:30.39%;" rowspan="2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">Balance under scheme not yet issued/allotted at end of the period:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.45%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:2.15pt;padding-right:2.15pt;padding-top:0pt;text-align:left;vertical-align:top;width:62.15%;" rowspan="2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">2015 HUTCHMED Share Option Scheme: 45,775,868 ordinary shares of US$0.1 each</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="display:none;vertical-align:middle;width:30.39%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"></td><td style="vertical-align:top;width:4.45%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="display:none;vertical-align:middle;width:62.15%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"></td></tr><tr style=""><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">8.</p></td><td style="color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:2.15pt;padding-right:2.15pt;padding-top:0pt;text-align:left;vertical-align:top;width:30.39%;" rowspan="5"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">Number and class of securities originally listed and the date of admission:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.45%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:2.15pt;padding-right:2.15pt;padding-top:0pt;text-align:left;vertical-align:top;width:62.15%;" rowspan="4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">25,198,880 ordinary shares of US$0.1 each admitted on June 17, 2019 <font style="font-size:11pt;">(</font>to replace the Company&#8217;s previous block admission schemes following the Company&#8217;s share subdivision which took effect on May 30, 2019)</p></td></tr><tr style="height:2.4pt;"><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="display:none;vertical-align:middle;width:30.39%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"></td><td style="vertical-align:top;width:4.45%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="display:none;vertical-align:middle;width:62.15%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"></td></tr><tr style=""><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="display:none;vertical-align:middle;width:30.39%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"></td><td style="vertical-align:top;width:4.45%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="display:none;vertical-align:middle;width:62.15%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"></td></tr><tr style=""><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="display:none;vertical-align:middle;width:30.39%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"></td><td style="vertical-align:top;width:4.45%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="display:none;vertical-align:middle;width:62.15%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"></td></tr><tr style=""><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="display:none;vertical-align:middle;width:30.39%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"></td><td style="vertical-align:top;width:4.45%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.62%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:57.52%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">9.</p></td><td style="vertical-align:top;width:30.39%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">Total number of securities in issue at the end of the period:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.45%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:62.15%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">872,327,620 ordinary shares of US$0.1 each</p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:33.39%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">Name of contact:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.45%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:62.15%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">Weiguo Su / Johnny Cheng</p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:33.39%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">Address of contact:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.45%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:62.15%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">Level 18, The Metropolis Tower, 10 Metropolis Drive, Hung Hom, Kowloon, Hong Kong </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:33.39%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">Telephone number of contact:</p></td><td style="vertical-align:top;width:4.45%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:62.15%;margin:0pt;padding:0pt 2.15pt 0pt 2.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;">+852 2121 8200</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"> <font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:4.47%;margin-right:4.47%;margin-top:30pt;page-break-after:always;width:91.06%;border-width:0;"><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">About HUTCHMED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">HUTCHMED (Nasdaq/AIM:&#8203;HCM; HKEX:&#8203;13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:10pt 0pt 6pt 0pt;"><b style="font-weight:bold;">CONTACTS</b></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:2.15pt 0pt 2.15pt 0pt;"><tr style="height:1pt;"><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Investor Enquiries</b></p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+852&#160;2121&#160;8200 / <u style="color:#0000ff;text-decoration-line:underline;text-decoration-style:solid;">ir@hutch-med.com</u></p></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Media Enquiries</b></p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FTI&#160;Consulting &#8211;</p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+44&#160;20&#160;3727&#160;1030&#160;/ <u style="color:#0000ff;text-decoration-line:underline;text-decoration-style:solid;">HUTCHMED@fticonsulting.com</u></p></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">   Ben Atwell / Tim Stamper</font></p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">   +44&#160;7771&#160;913&#160;902&#160;(Mobile)&#160;/ +44&#160;7421&#160;898&#160;348 (Mobile)</font></p></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Brunswick &#8211; Zhou Yi</p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+852&#160;9783&#160;6894&#160;(Mobile)&#160;/ <u style="color:#0000ff;text-decoration-line:underline;text-decoration-style:solid;">HUTCHMED@brunswickgroup.com</u></p></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Panmure Liberum</b></p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Nominated Advisor and Joint Broker</i></p></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Atholl Tweedie&#160;/ Emma Earl&#160;/ Rupert Dearden</p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+44&#160;20&#160;7886&#160;2500</p></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Cavendish</b></p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Joint Broker</i></p></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Geoff Nash&#160;/ Nigel Birks</p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+44&#160;20&#160;7220&#160;0500</p></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Deutsche Numis</b></p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Joint Broker</i></p></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Freddie Barnfield / Jeffrey Wong / Duncan Monteith</p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+44 20 7260 1000</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:4.47%;margin-right:4.47%;margin-top:30pt;page-break-after:avoid;width:91.06%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>hcm-20251229xex99d2.htm
<DESCRIPTION>EX-99.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 12/29/2025 10:51:16 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;width:32.3%;">&#9;</font><font style="display:inline-block;width:11.76%;">&#9;</font><font style="display:inline-block;width:38.55%;">&#9;</font></font><font style="display:block;height:1px;left:0pt;position:absolute;width:100%;z-index:0;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><b style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:bold;">Exhibit 99.2</b></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:11pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><img src="hcm-20251229xex99d2001.gif" alt="Graphic" style="display:inline-block;height:44.95pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:160.15pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="white-space:pre-wrap;">                                              </font><font style="font-size:12pt;white-space:pre-wrap;">                                                                                                          </font><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><a name="_Hlk162538399"></a><a name="_Hlk181768051"></a><b style="font-weight:bold;">Press Release</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.31;text-align:center;margin:0pt;"><b style="font-weight:bold;">HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:center;margin:0pt 0pt 12pt 0pt;">&#8212;&#160;NDA supported by results from a Phase II registration trial in China&#160;&#8212;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:center;margin:0pt 72pt 12pt 72pt;">&#8212;&#160;Second most common form of liver cancer after hepatocellular carcinoma, with generally poorer long-term survival in comparison&#160;&#8212;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Hong Kong, Shanghai &amp; Florham Park, NJ &#8212;&#160;Monday, December 29, 2025:</b> HUTCHMED (China) Limited (&#8220;HUTCHMED&#8221;) (Nasdaq/AIM:&#8203;HCM; HKEX:&#8203;13) today announces that <a name="_Hlk195259555"></a>the New Drug Application (&#8220;NDA&#8221;) for fanregratinib (HMPL-453) for the treatment of adult patients with advanced, metastatic or unresectable &#160;intrahepatic cholangiocarcinoma (&#8220;ICC&#8221;) with fibroblast growth factor receptor (&#8220;FGFR&#8221;) 2 fusion/rearrangement who have previously received systemic therapy has been accepted and granted priority review by the China National Medical Products Administration (&#8220;NMPA&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">Fanregratinib (HMPL-453) is a novel, selective, oral inhibitor targeting FGFR 1/2/3. ICC is a highly aggressive malignancy arising from the intrahepatic biliary epithelium. It accounts for 8.2-15.0% of primary liver cancers, and consequently it is the second most common type after hepatocellular carcinoma. In recent years, the incidence of ICC has continued to rise, with a 5-year overall survival rate of approximately 9%.<sup style="font-size:8.25pt;vertical-align:top;">1</sup>&#160;Approximately 10-15% of ICC patients globally have tumors harboring FGFR2 fusions or rearrangements.<sup style="font-size:8.25pt;vertical-align:top;">2,3</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">This NDA is supported by data from a single-arm, multi-center, open-label, Phase II registration study&#160;in China. The study has met its primary endpoint of objective response rate (ORR). Results from the secondary endpoints including progression-free survival (PFS), disease control rate (DCR), duration of response (DoR) and overall survival (OS) also support the primary endpoint findings. Full results will be submitted for presentation at an upcoming scientific conference. Additional details may be found at clinicaltrials.gov using identifier&#160;NCT04353375. </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;text-align:justify;margin:0pt 0pt 6pt 0pt;">About Fanregratinib</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">Fanregratinib (HMPL-453) is a novel, highly selective and potent inhibitor targeting FGFR 1, 2&#160;and&#160;3. Aberrant FGFR signaling has been found to be a driving force in tumor growth, promotion of angiogenesis and resistance to anti-tumor therapies. Abnormal FGFR gene alterations are believed to be the drivers of tumor cell proliferation in several solid tumor settings. HUTCHMED currently retain all rights to fanregratinib worldwide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;text-align:justify;margin:0pt 0pt 6pt 0pt;">About HUTCHMED</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">HUTCHMED (Nasdaq/AIM:&#8203;HCM; HKEX:&#8203;13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:4.47%;margin-right:4.47%;margin-top:30pt;page-break-after:always;width:91.06%;border-width:0;"><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;">Forward-Looking Statements </font><a name="_Hlk136438441"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:italic;text-align:justify;margin:0pt;">This press release contains forward-looking statements within the meaning of the &#8220;safe harbor&#8221; provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED&#8217;s current expectations regarding future events, including its expectations regarding the review of a NDA for fanregratinib for the treatment of ICC with the NMPA and the timing of such review, therapeutic potential of fanregratinib for the treatment of patients with ICC and the further development of fanregratinib in this and other indications. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding the timing and outcome of clinical studies and the sufficiency of clinical data to support NDA approval of fanregratinib for the treatment of patients with ICC or other indications in China or other jurisdictions, its potential to gain approvals from regulatory authorities on an expedited basis or at all, the safety profile of fanregratinib, HUTCHMED&#8217;s ability to fund, implement and complete its further clinical development and commercialization plans for fanregratinib and the timing of these events. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED&#8217;s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="font-size:9pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:10pt 0pt 6pt 0pt;"><b style="font-weight:bold;">CONTACTS</b></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:2.15pt 0pt 2.15pt 0pt;"><tr style="height:1pt;"><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Investor Enquiries</b></p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+852&#160;2121&#160;8200 / <u style="color:#0000ff;text-decoration-line:underline;text-decoration-style:solid;">ir@hutch-med.com</u></p></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Media Enquiries</b></p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FTI&#160;Consulting &#8211;</p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+44&#160;20&#160;3727&#160;1030&#160;/ <u style="color:#0000ff;text-decoration-line:underline;text-decoration-style:solid;">HUTCHMED@fticonsulting.com</u></p></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">   Ben Atwell / Tim Stamper</font></p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">   +44&#160;7771&#160;913&#160;902&#160;(Mobile)&#160;/ +44&#160;7421&#160;898&#160;348 (Mobile)</font></p></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Brunswick &#8211; Zhou Yi</p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+852&#160;9783&#160;6894&#160;(Mobile)&#160;/ <u style="color:#0000ff;text-decoration-line:underline;text-decoration-style:solid;">HUTCHMED@brunswickgroup.com</u></p></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Panmure Liberum</b></p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Nominated Advisor and Joint Broker</i></p></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Atholl Tweedie&#160;/ Emma Earl&#160;/ Rupert Dearden</p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+44&#160;20&#160;7886&#160;2500</p></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Cavendish</b></p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Joint Broker</i></p></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Geoff Nash&#160;/ Nigel Birks</p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+44&#160;20&#160;7220&#160;0500</p></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Deutsche Numis</b></p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Joint Broker</i></p></td></tr><tr style=""><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Freddie Barnfield / Jeffrey Wong / Duncan Monteith</p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+44 20 7260 1000</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">_________________________________________</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">REFERENCES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:8pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:3.3pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:6pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Expert consensus on precision detection of intrahepatic cholangiocarcinoma (2024 edition). </font><i style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:italic;font-weight:normal;">Chin J Clin Med</i><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">. 2025;32(1):1-18.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:8pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:3.3pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:6pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Arai Y, Totoki Y, Hosoda F, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.&#160;</font><i style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:italic;font-weight:normal;">Hepatology.</i><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">&#160;2014;59:1427&#8211;34.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:3.3pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:6pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer.&#160;</font><i style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:italic;font-weight:normal;">Nat Genet.</i><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">&#160;2015;47:1003&#8211;10.</font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:4.47%;margin-right:4.47%;margin-top:30pt;page-break-after:avoid;width:91.06%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>hcm-20251229xex99d1001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hcm-20251229xex99d1001.gif
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MH''GQH8Y=RX0 $H>O5XZ'! @($#KUP<PJ,G31#*! "OU%D0CP/#M"P1K0)!
M7,**Q KQN(@P0<($"$8(8E'AG'CSZM6;0R"39\OP"<VOA_^?H.)%DC9$HQ98
MG\ .0CP7#A<@<."Q0 T"3JZG?#"#_/48%332!@*L=P !8 B81P@%1B7 #@N-
MY 14J^%PFH)HT!<5 1@05$0$?X$'7@H11$?0$A+$M=9:$1PQD W,K25!&1<J
MU$6,<A6!4!TLB B>&1RI=R "N@F(P0#K147'0!O(MYH7"1VY5 $!&L1!?E$-
MD&"1=E#P'Y41YN$$EA4FE 8!!J D0(<O@BCB&0+5X)R(*D10@T!EN%FGBP+!
MJ )X$@#)4!<0C%AB0D442EX$6-0H49(&%DD0?/\=L.1 =ECPY4F<$:">>@-(
MX6A!'%"H94)*Z7?  6G.MZ&%>3S_0:8 %DHJT)EI'LBF0#?,"1Z<#)&1(G@M
M#O2ACVN%F*R(+"1V8XA_I?"GLB-*  $3>&6K[;9XX3!K"-R&*^ZXW"H555->
M8%G  !;D,898#3! @KL,*+#  D3D\<,"7BU@5A)N G8#'DA $,$#++Q![L(,
M>S22MTL)D$.Z2Q'0;AC\9K45"0QXQ0!8\"H0Q%E^ 78$H2'.U?#*++=<$,#1
M0J"CI*T:0  "R!T4WU+U#:3!EQC9FH=_D&+4A @XY(!#T@EHN!X(.BRM= YP
MQ*KN@05\T$047T31A <Z7.B$DTV)E$>&2PVP:QXWN%EM# G=D-:*<O&91PTQ
MKI6$%EAD_\&W%EGXC87">=PHH@0O*)%$$D7$P(*O@+H@-$1)KNKJY>L%L$.3
M/-N7Q\_Z$<"?05*V6J5,>5R9=H(%=>GI4FDT-*9^ZWEJNX8(?*$J 1D0!*-:
MS;FQ!(@D-MK%L->:03R)+HZ$-[(BJC6G!"SH]2RQ)AXTO(@0+!%DZ$2..M#.
M!KHG4!-D#M ['KJ-!$5^JZJ=$.=9CCX0#U"5+Y"M>LWN(*P*.E/$UN:G-\GD
M!=*:@.0&DB<1%2M.>9N1^%!7N( =:B2ZN8,+YB07N+GL@R#\R$AVD!\#,"5L
MDPNA"E=X%'.M9B44G-1#^,?"&J[0A0) 01K@MYH-Y($-'1L+ _],@) A*& $
M8U' %/)PA9(]P'LIM*$4\?(P"J$K *UBE[LR%J\2P(%C'@,95LCRKY)!X&0E
M4]D4UY@M%UXQ=.T: Q>UPI4@QDN,6!$9R>(" ;>43(%L#*1=,N6: %C@,2)@
M3(%8%Y9[,4 ,>>#" NRE@"'DH0XE4$"]3L"^OD0K H*YP0.LI0+T"/*4@N2+
M&0>&RE9J)(H=@25!ZK""X4! !7,X"$J$E#,!D4])/ON2_0@B)?U@A .'694R
MHZ(J9<8/! *APP5,8CEG*G, 31#(V)19-H2DH7+R,U; Y++ A,2 @R3*GA'R
M%J)I_>5/U/'@C?Y$IP2.B)[.Z<($([+_R_7@+"$[6\IC1@*ZV@T3,LD$T&G:
MEP<"K>Y"[!-(&)RV+M-$=']%\A]3 &@0M,5O;6U3UE\B8(.#'$%1P&/>A>0T
MH@G02%(8',BSU!*!F17D#3T"3YT\N!%(T<<.>%C2'? P5#O8(:"K<@]!D92D
MTQ7$/[1SZD!4ER763>H"3L-,F#0Z@)70@:CL VI5?$I XI%'3B.%8AZTP!RU
MQ""E$K ;WO#)G3L,%:QVO>@\690]@R0J+HS:9T,@M9X!O(8U S")'8H9%<\5
M=#\)@:KI$$(_J6R)('>@@-,.$+ODB$E=-C.L $1#  #P( Y,+<":/&36"0#I
M0\!# O!JF@=A_WU2KGDCE@0BP-O=2N")%[I>G:(CM"7,307=^QXS$6 ^@U#*
MF9X# 9D"X 2$W"$!J3W ; [BT*J*K[(">(+LIHL",VEH-2#%D02 E0<8..<O
M$H ! RW8O+O%B#HT\JSAB*6C@]SA<< +5) JQUR .JEG KGN>:/2A#B,Y YH
MZ,#52F.V[EIV@E(RD-IZX(4TP$$-:@"#%'BPI#$9J&PPS8, 4<*A_;$MM^Q5
M2 ,793<8M?0*;3"#CG5\AAV?823[[2#@^+:$&"!++<WJ"&M&J]CW4"  G"F0
MYP8"!Q"HEC &6A4!1HL!*$4Q P#8<F*_(-@\2 $#JOV,9_)SJ28 0/\T (#A
M07:XY=NT:Z6C) X$!+40,@PG K^U:1Z. &C?5J?0Q0&1LT;96^( FK?,44$,
MM"!+5UHZ6W"0BFH1?.E.3Q%B#I*SIT<=PBI&+#>D3C4(<0BN2JOZU=VBD$KR
M  +7](;,>0B+ NS%!=3II0XDH*0)$J/!!T0  BWHB5Y<#>M6FOI_7J"0Q;;H
ML1(D9@U"",)-\C"#D/UK>;3% QF.< 4Y-/O<)+&B4Z0=QP4@L8MX,(&[1] Q
M/(3EW64Y2\"@\X:2D13=L ;U1J.=MG:_FXY@_$I8^E5&/AH!9?"E"\!)_>R!
ML]M=\$*X'1>0$V_O<2U]A#@Y)ZYJ@=,J71K_;G>UV9#P.]X[CPT'^</GUAR)
MDWS4^.-F$]3 PP!P( ]O\,H(%G""/,A[!.^^ Q&.F$0J[/$OT&D#\9![IYN3
M.@XZZ( .+H6'K\&$(#2AP;;=-8,95&$@.=G)4#PY4L'@(0LV,((;F&UU2]-0
MAN\9B!(")@&WN[CN@.^()V544N=*!);,%EK[%!^FF,;2LQM!/-[QTL28><\@
M7\A\YL&00C1H_@N<'XCG/]_+W7B!]&?[O.I7_WDO5*T@<!@Q#D   A'L  K;
MS4,<3I]Y+^3>('=H_>G>L&,=NZ$A<BA#CW5,.)\4__G/+T-/ZE &Z!>_#4-Q
MR$CD8(08%*'Y!6&5_WH24'IB)G-5CG52 0XJD S09RG'3"@SA<0S:YK/#B#@
M##.M*14+2(B:98(0'B45Z:4"G]0H"K$%[S52]>5G(Q(7$.@CTM(3QP,\T',X
MQ!$#Q_<1D+(JY3<^"64I P%5)R$Z^Y1A"H4!;V9KO4%8K5%( P  XI4ZZI(E
M 0!EB<5FVB1KM3)GYQ5.?6)6([4%"6$&T<,B]856AV,PD'9LO.4 ?'(]@,*$
MQ2&!S<%G&U$S-_.!I_%+G(8?M,-^0P,TAD<@&F95!4$^!W( 4E40$[(4*'80
M&9(DX302(94L\)5?!>$&+058]55 5]@0PO5 ,D$&CV. (*<%'5$Y6VA@T/\5
M3%$5):D%)K:"3 ]E$#V0/FN3$&]X+ARU&UF57M#24J8T$'- 3]%3-R\R+,VA
MAS:2(C355R[&5CZB MF7$943%5R8!T>R?^E7,3$A-"@()@=AB?4C/@4E%1:U
M$!K537)X7JNE%[]C@>UD;@G6(REE*$DX+&J!A69S/>FT3S& (Q&@B!M1?_R'
M  BP*A_0BP9R*0U%39"%$%#55!-D8:?")4TC))W%C/"#$@>0  >@CLJTCCR@
M*JLE3LI"!BT@(TFF'-7Q EN AX1H8W2B BR@ AJID2O0D=9(!NHEBR<2 09(
M(MC24X3%?Y;S!1EP-0/U.378ANTWB3)Y)6<H0Z[_HRK]J! :!9#\-P >H 9.
MDI!!&&!K, <^\@)WPXUW4 ;<&%=M@HI6J!9U4G@5-%O]I2## SS)17<$82 &
MP@$=P %B298:$#9(U3-+%88G2(;%* "YHE7ZN%F_QXGJ0@ ),)9DN9<;D 9J
M\'ZZXCNP^"-Y8(07. 'H85L,>"&_(R(Q4 .0&9DU8 ,Q "1 1I+\E1##0T\1
M<'D:D9)*]7>G@0&;]9(>,"M04AGGQUF&1U7S@88#H2EIDYK^&#'EE6*XPF)E
MA8K XI3((@'<D0=Y$B+%XCR^(D&P-$_2<D$'\3S$D@4#5CE<"!\N>2$Y,%TH
M9!"99B _58;I YL"D4AP_WB;M?D_^Y2;-B.**P(G(Z& *R(!1#@2PXF$ R$G
M^.2*"1%DT&%XQX.(:G&+CP*6B/$>7OB28#  K3(?45",9--J;_E0##510B(
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M \U5$&"0 QJPCEF& 2A@!0R%$$V0 SL@JE33$&'  QY@ <!J 1D@ CS 'V&
MJJ+J% D1!\@:-3Y $%V0!$LPK4I@C0OQ!DHPK4N0!,$Y$&:P!-FJK>(JKDPP
2$FX@K>.JK5B@!68 H!\1$  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>hcm-20251229xex99d2001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hcm-20251229xex99d2001.gif
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MH''GQH8Y=RX0 $H>O5XZ'! @($#KUP<PJ,G31#*! "OU%D0CP/#M"P1K0)!
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M^.2*"1%DT&%XQX.(:G&+CP*6B/$>7OB28#  K3(?45",9--J;_E0##510B(
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M \U5$&"0 QJPCEF& 2A@!0R%$$V0 SL@JE33$&'  QY@ <!J 1D@ CS 'V&
MJJ+J% D1!\@:-3Y $%V0!$LPK4I@C0OQ!DHPK4N0!,$Y$&:P!-FJK>(JKDPP
2$FX@K>.JK5B@!68 H!\1$  [

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
